Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Standard

Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. / Dejgaard, Thomas Fremming; Johansen, Nanna B; Frandsen, Christian S S; Asmar, Ali; Tarnow, Lise; Knop, Filip K; Madsbad, Sten; Andersen, Henrik U.

I: Diabetes, Obesity and Metabolism, Bind 19, Nr. 5, 05.2017, s. 734–738.

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Harvard

Dejgaard, TF, Johansen, NB, Frandsen, CSS, Asmar, A, Tarnow, L, Knop, FK, Madsbad, S & Andersen, HU 2017, 'Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes', Diabetes, Obesity and Metabolism, bind 19, nr. 5, s. 734–738. https://doi.org/10.1111/dom.12841

APA

Dejgaard, T. F., Johansen, N. B., Frandsen, C. S. S., Asmar, A., Tarnow, L., Knop, F. K., Madsbad, S., & Andersen, H. U. (2017). Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 19(5), 734–738. https://doi.org/10.1111/dom.12841

Vancouver

Dejgaard TF, Johansen NB, Frandsen CSS, Asmar A, Tarnow L, Knop FK o.a. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes, Obesity and Metabolism. 2017 maj;19(5):734–738. https://doi.org/10.1111/dom.12841

Author

Dejgaard, Thomas Fremming ; Johansen, Nanna B ; Frandsen, Christian S S ; Asmar, Ali ; Tarnow, Lise ; Knop, Filip K ; Madsbad, Sten ; Andersen, Henrik U. / Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. I: Diabetes, Obesity and Metabolism. 2017 ; Bind 19, Nr. 5. s. 734–738.

Bibtex

@article{1d296ce1233f4074b83bb3ac96fd4ddd,

title = "Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes",

abstract = "We investigated the short-term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m(2) ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial. At baseline and after 24 weeks of treatment, 24-hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima-media thickness were evaluated. Compared with placebo, liraglutide increased 24-hour heart rate by 4.6 beats per minute (BPM); P = .0015, daytime heart rate by 3.7; P = .0240 and night-time heart rate by 7.5 BPM; P < .001 after 24 weeks. Diastolic nocturnal blood pressure increased by 4 mm Hg; P = .0362 in the liraglutide group compared with placebo. In conclusion, in patients with long-standing type 1 diabetes, liraglutide as add-on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment.",

keywords = "Journal Article",

author = "Dejgaard, {Thomas Fremming} and Johansen, {Nanna B} and Frandsen, {Christian S S} and Ali Asmar and Lise Tarnow and Knop, {Filip K} and Sten Madsbad and Andersen, {Henrik U}",

note = "{\textcopyright} 2016 John Wiley & Sons Ltd.",

year = "2017",

month = may,

doi = "10.1111/dom.12841",

language = "English",

volume = "19",

pages = "734–738",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "5",

}

RIS

TY - JOUR

T1 - Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes

AU - Dejgaard, Thomas Fremming

AU - Johansen, Nanna B

AU - Frandsen, Christian S S

AU - Asmar, Ali

AU - Tarnow, Lise

AU - Knop, Filip K

AU - Madsbad, Sten

AU - Andersen, Henrik U

PY - 2017/5

Y1 - 2017/5

N2 - We investigated the short-term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m(2) ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial. At baseline and after 24 weeks of treatment, 24-hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima-media thickness were evaluated. Compared with placebo, liraglutide increased 24-hour heart rate by 4.6 beats per minute (BPM); P = .0015, daytime heart rate by 3.7; P = .0240 and night-time heart rate by 7.5 BPM; P < .001 after 24 weeks. Diastolic nocturnal blood pressure increased by 4 mm Hg; P = .0362 in the liraglutide group compared with placebo. In conclusion, in patients with long-standing type 1 diabetes, liraglutide as add-on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment.

AB - We investigated the short-term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m(2) ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial. At baseline and after 24 weeks of treatment, 24-hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima-media thickness were evaluated. Compared with placebo, liraglutide increased 24-hour heart rate by 4.6 beats per minute (BPM); P = .0015, daytime heart rate by 3.7; P = .0240 and night-time heart rate by 7.5 BPM; P < .001 after 24 weeks. Diastolic nocturnal blood pressure increased by 4 mm Hg; P = .0362 in the liraglutide group compared with placebo. In conclusion, in patients with long-standing type 1 diabetes, liraglutide as add-on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment.

KW - Journal Article

U2 - 10.1111/dom.12841

DO - 10.1111/dom.12841

M3 - Letter

C2 - 27935240

VL - 19

SP - 734

EP - 738

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 5

ER -

ID: 176440466